ID: MRFR/HC/0123-HCRR | July, 2017 | Region: Global | 110 pages | Half-Cooked Research Reports
Market Synopsis of Global Cancer Biological Therapy Market:
Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors.
The market driving factors for global cancer biological therapy market are increasing cancer survival rates, growing demand for advanced therapies such as biological therapy, growth of cancer healthcare facilities in emerging countries etc. However the less number of side effects associated with biological therapy as compared to conventional treatment methods is the critical growth factor. Conventional cancer treatment methods like chemotherapy, radiotherapy give effective result, but along with that, these methods also show its counter effects on body. The side effects may include, loss of hair, weekend immune system, and such others depending upon the type and phase of cancer. Biological therapies help to reduce the level of side effects as compared to other treatment methods. Biological therapies are giving the same amount of success rate for curing the cancer patient with 1st stage cancer approximately 27% to 35%. Thus due to low level of side effects and high success rate this therapy is highly accepted and hence, helps to drive the market growth.
Another driver is the changing lifestyle and increasing smoking population in Middle East & Africa. It was also noted that, smoking population in Middle East has increased rapidly. For instance, between 1990 and 2012, rates of smoking in Lebanon have increased nearly by 500%. In fact, a study in the Economist pointed out that in 2012, the average Lebanese person smoked 2,379 cigarettes.
The critical restraints include high cost of cancer biological therapy and the risks involved in the treatment. The poor rate of healthcare insurance penetration in developing regions is also a drag on the market.
Considering all these factors the market for Cancer Biological Therapy is expected to reach $ 82,276.8 million by the end of 2023, this market is projected to growing at a CAGR of ~ 4.7 % during 2017-2023.
Figure 1 Global Cancer Biological Therapy Market by Type, 2016 (% Market Share)
The global Cancer Biological Therapy market is segmented on the basis of phases. Based on the phases, the market has been segmented as phase I, phases II and phases III. Based on the type, the market has been segmented as monoclonal antibodies, interferons, interleukins, cancer growth inhibitors, gene therapy and colony-stimulating factors. Based on the end-users, the market has been segmented as hospitals & clinics, cancer research centers and laboratories.
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and rising awareness. Asia pacific region will be the fastest region because of large unmet needs which will be led by China and India. The Middle East and Africa market will be led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa is expected to be a laggard due to poor economic and political conditions.
Key players of Global Cancer Biological Therapy Market:
Key players profiled in the report are Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, ELI Lilly and Company, F. Hoffmann-La Roche AG, EnGeneIC Ltd, Merck & Co., Inc., Novartis,Pfizer Inc. and others.
The report for Global Cancer Biological Therapy Market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Table of Contents
1 Report Prologue
2.2 Scope of Study:
2.3 Research Objective
2.4 Market Structure
3 Research Process:
3.1.1 Primary Research:
3.1.2 Secondary Research:
4.2.1 Increasing Cancer Survival Rate
4.2.2 Growing Demand for Advanced Therapies
4.2.3 Less Number of Side Effects as Compared to Conventional Treatment Methods
4.2.4 Growth of Cancer Healthcare Facilities in Emerging Countries
4.2.5 Changing Lifestyle and Increasing Smoking Population in Middle East & Africa
4.3.1 High cost of Cancer Biological Therapy
4.4.1 UnTapped Types of Cancers
4.5 Macroeconomic Indicators
5 Global Cancer Biological Therapy, By Phases
6 Global Cancer Biological Therapy Market, By Type
6.2 Monoclonal Antibodies
6.5 Cancer growth inhibitors
6.6 Gene Therapy
6.7 Colony-Stimulating Factors
7 Global Cancer Biological Therapy Market, By End-Users
7.2 Hospitals & Clinics
7.3 Cancer Research Centers
8 Global Cancer Biological Therapy, By Region
8.2 North America
8.3.6 Rest Of Europe
8.4.4 Republic of Korea
8.4.5 Rest of Asia-Pacific
8.5 Middle East & Africa
8.5.1 Middle East
9 Competitive Landscape
9.1 Market Share Analysis
10 Company Profile
10.1 Amgen Inc.
10.1.2 Product/Business Segment Overview
10.1.3 Financial Overview
10.1.4 Key Development
10.2 Bristol-Myers Squibb
10.2.2 Product/Business Segment Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.3 Celgene Corporation
10.3.2 Product/Business Segment Overview
10.3.3 Financial Overview
10.3.4 Key Developments
10.4 ELI Lilly and Company
10.4.2 Product/Business Segment Overview
10.4.3 Financial Overview
10.4.4 Key Developments
10.5 EnGeneIC Ltd
10.5.2 Product/Business Segment Overview
10.5.3 Financials Updates
10.5.4 Key Developments
10.6 F. Hoffmann-La Roche AG
10.6.2 Product/Business Segment Overview
10.6.3 Financial Updates
10.6.4 Key Developments
10.7 Merck & Co., Inc.
10.7.2 Product/Business Segment Overview
10.7.3 Financial Updates
10.7.4 Key Developments
10.8.2 Product/Business Segment Overview
10.8.3 Financial Updates
10.8.4 Key Developments
10.9 Pfizer Inc.
10.9.2 Product/Business Segment Overview
10.9.3 Financial Updates
10.9.4 Key Developments